Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
26. August 2022 16:30 ET
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (August 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
02. August 2022 06:00 ET
|
Allarity Therapeutics, Inc.
New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the Company’s future funding and commercial...
Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.
11. Juli 2022 07:00 ET
|
Allarity Therapeutics, Inc.
Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Press ReleaseCambridge, MA, U.S.A. (July 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the...
Allarity Therapeutics Announces Executive Leadership Transition
29. Juni 2022 16:01 ET
|
Allarity Therapeutics, Inc.
Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release Cambridge, MA, U.S.A. (June 29, 2022) — Allarity...
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.
15. Juni 2022 09:25 ET
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (June 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Reports First Quarter 2022 Financial Results
27. Mai 2022 17:37 ET
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 27, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
18. Mai 2022 17:30 ET
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 18, 2022) — Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced today that its press release issued under the headline “Allarity Therapeutics Reports Fourth Quarter and Full...
Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
16. Mai 2022 19:40 ET
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (May 16, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
22. April 2022 17:00 ET
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (April 22, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Provides Update on Dovitinib Program
15. März 2022 08:32 ET
|
Allarity Therapeutics, Inc.
FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...